(VIANEWS) - Acadia Realty Trust (AKR), Reynolds Consumer Products (REYN), Novo Nordisk A/S (NVO) are the highest payout ratio stocks on this list.
Here's the data we've collected of stocks with a high payout ratio up to now. The payout ratio in itself isn't a promise of a future good investment but it's an indicator of whether dividends are being paid and how the company chooses to distribute them.
When researching a potential investment, the dividend payout ratio is a good statistic to know so here is a list of some companies with an above 30% payout ratio.
1. Acadia Realty Trust (AKR)
194.12% Payout Ratio
Acadia Realty Trust is an equity real estate investment trust focused on delivering long-term, profitable growth via its dual - Core and Fund - operating platforms and its disciplined, location-driven investment strategy. Acadia Realty Trust is accomplishing this goal by building a best-in-class core real estate portfolio with meaningful concentrations of assets in the nation's most dynamic corridors; making profitable opportunistic and value-add investments through its series of discretionary, institutional funds; and maintaining a strong balance sheet.
Earnings Per Share
As for profitability, Acadia Realty Trust has a trailing twelve months EPS of $0.05.
PE Ratio
Acadia Realty Trust has a trailing twelve months price to earnings ratio of 280.39. Meaning, the purchaser of the share is investing $280.39 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 2.37%.Annual Top and Bottom Value
Acadia Realty Trust stock was valued at $14.30 as of 07:23 EST. This is way below its 52 week high of $22.64, and far above its 52 week low of $12.28.
Volume
Today's last reported volume for Acadia Realty Trust is 253745 which is 61.34% below its average volume of 656475.
Dividend Yield
Morningstar, Inc. has stated that the next dividend payment will be on Sep 28, 2022. The forward dividend rate for 2020 is 0.72, and the forward dividend yield is 5.26.
Moving Average
Acadia Realty Trust's value is below its 50-day moving average of $14.35 and way below its 200-day moving average of $16.90.2. Reynolds Consumer Products (REYN)
70.23% Payout Ratio
Reynolds Consumer Products Inc. manufactures and markets products for the cooking, waste, storage and tableware categories. There are four main segments to it: Reynolds Cooking & Baking; Hefty Waste & Storage; Hefty Tableware; and Presto Products. Reynolds Cooking & Baking produces foil, aluminum pans, paper for baking, paper for freezer, paper for cooking, paper for wrapping food in, paper bags and paper wraps. It also sells slow cooker liners, under Reynolds Wrap, Reynolds KITCHENS and E-Z Foil brand names in the United States. Hefty Waste & Storage offers garbage bags and food storage bags, both under the Hefty Ultra Strong or Hefty Strong brand. The Hefty EnergyBag program, which includes blue, clear, plastic, recyclable, and compostable bags as well as bags made of recycled materials and bags, is also available in this segment. Hefty Tableware offers disposable and compostable dishes, plates, bowls and platters as well as cutlery. Presto Products sells store-brand products, including food storage bags and trash bags as well as reusable storage containers. Reynolds Consumer Products Inc. sells both store and brand-name products to supermarkets, bulk merchants, warehouse clubs and discount chains. They also offer dollar stores and drug stores as well as home improvement and military stores. It was established in 1947 in Lake Forest, Illinois. Reynolds Consumer Products Inc. is a subsidiary to Packaging Finance Limited.
Earnings Per Share
As for profitability, Reynolds Consumer Products has a trailing twelve months EPS of $1.58.
PE Ratio
Reynolds Consumer Products has a trailing twelve months price to earnings ratio of 19.23. Meaning, the purchaser of the share is investing $19.23 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.87%.Volume
Reynolds Consumer Products' last reported volume is now 130313, which is 74.25% lower than its 506247 average volume.
Sales Growth
Reynolds Consumer Products's sales growth is 11.3% for the current quarter and 10.6% for the next.
3. Novo Nordisk A/S (NVO)
46.51% Payout Ratio
Novo Nordisk A/S is a global healthcare company that specializes in research, development and manufacture of pharmaceutical products. The company operates in two areas: Diabetes and Obesity Care and Biopharm. Diabetes and Obesity Care provides products for insulins, GLP-1, related delivery systems and oral anti-inflammatory products. Biopharmaceuticals offers products that address haemophilia and growth disorders as well as hormone replacement therapy. To explore new delivery strategies, Novo Nordisk A/S has entered into research agreements with Lumen Bioscience, Inc. and Gilead Sciences, Inc. It was established in Denmark in 1923. The headquarters are located in Bagsvaerd.
Earnings per Share
Novo Nordisk A/S' trailing 12 month EPS is $2.92.
PE Ratio
Novo Nordisk A/S's trailing 12-month price-to-earnings ratio is 47.53. The purchaser of the shares is therefore investing $47.53 per dollar in annual earnings.
For the 12 trailing months, the company's return-on-equity, which is a measure of the profitability and shareholder equity for a business, was 72.19%.Revenue Growth
Year-on-year quarterly revenue growth grew by 24.9%, now sitting on 157.25B for the twelve trailing months.
Moving Average
Novo Nordisk A/S's value is way higher than its 50-day moving average of $112.44 and way above its 200-day moving average of $109.57.Yearly Top and Bottom Value
Novo Nordisk A/S's stock is valued at $138.79 at 07:23 EST, above its 52-week high of $130.85.
4. MarketAxess Holdings (MKTX)
42.86% Payout Ratio
MarketAxess Holdings Inc., together with its subsidiaries, operates an electronic trading platform for institutional investor and broker-dealer companies worldwide. It offers the access to liquidity in the U.S. investment-grade bonds, U.S. high-yield bonds, and U.S. Treasuries, as well as municipal bonds, emerging market debts, Eurobonds, and other fixed income securities. The company, through its Open Trading protocols, executes bond trades between and among institutional investor and broker-dealer clients in an all-to-all anonymous trading environment for corporate bonds. It also offers trading-related products and services, including composite+ pricing and other market data products to assist clients with trading decisions; auto-execution and other execution services for clients requiring specialized workflow solutions; connectivity solutions that facilitate straight-through processing; and technology services to optimize trading environments. In addition, the company provides various pre-and post-trade services, such as trade matching, trade publication, regulatory transaction reporting, and market and reference data across a range of fixed-income and other products. MarketAxess Holdings Inc. was incorporated in 2000 and is headquartered in New York, New York.
Earnings per Share
MarketAxess Holdings' trailing 12 months EPS is $8.
PE Ratio
MarketAxess Holdings' trailing 12-month price-to-earnings ratio is 39.21. The purchaser of the shares is therefore investing $39.21 per dollar in annual earnings.
For the 12 trailing months, the company's return-on-equity, which is a measure of the profitability and shareholder equity for a business, was 23.45%.5. Novartis AG (NVS)
32.6% Payout Ratio
Novartis AG develops and manufactures healthcare products around the world. Two segments of the company are Innovative Medicines (Sandoz) and Healthcare Products. Innovative Medicines offers prescription medications for both patients and health care providers. The company also offers ophthalmology and neuroscience as well as immunology, dermatology, neurology, immunology, hepatology and metabolic medicine products. Sandoz produces, markets, and manufactures finished dosage form medications; active ingredients, as well as finished dosage forms, of small-molecule pharmaceuticals for third parties. It also sells generics and antiinfectives. The company also supplies active pharmaceutical ingredients, intermediates, primarily antibiotics; proteins- or other biotechnology based products; and services in biotechnology manufacturing. Novartis AG holds a collaboration and license agreement with Alnylam Pharmaceuticals for the development, manufacturing, and marketing of inclisiran. Kura Oncology, Inc. has been contracted to conduct clinical trials to assess the combined effect of Tipifarnib/Alpelisib on patients suffering from head and neck carcinoma. Basel is the headquarters of this company, which was founded in 1996.
Earnings Per Share
As for profitability, Novartis AG has a trailing twelve months EPS of $3.48.
PE Ratio
Novartis AG has a trailing twelve months price to earnings ratio of 26.55. Meaning, the purchaser of the share is investing $26.55 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 36.99%.